Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cynata TherapeuticsCYYNF Cash-to-Debt is No Debt (1) as of Dec. 2025, which is 100% below its 10-year median of 10,000.00. The stock has 1 warning sign investors should review. Among 1,393 Biotechnology companies, Cynata Therapeutics ranks better than 99.64% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cynata Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2025 was No Debt (1).
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cynata Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Cynata Therapeutics's Cash-to-Debt or its related term are showing as below:
CYYNF'
s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt
During the past 13 years, Cynata Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.
CYYNF's Cash-to-Debt is ranked better than 99.64% of 1393
companies
in the Biotechnology industry
Industry Median: 6.72
vs CYYNF: No Debt
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Cynata Therapeutics Cash-to-Debt Related Terms
Cynata Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Cynata Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CYYNF vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, Cynata Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cynata Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cynata Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Cynata Therapeutics's Cash-to-Debt falls into.
Cynata Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Jun. 2025 is calculated as:
Cynata Therapeutics had no debt (1).
Cynata Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2025 is calculated as:
Cynata Therapeutics had no debt (1).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash-to-Debt of No Debt <sup>(1)</sup> mean?
Cynata Therapeutics (CYYNF) has a Cash-to-Debt of No Debt (1) as of Dec. 2025. This is 100% below median its historical median of 10,000.00. Over the past decade, Cynata Therapeutics' Cash-to-Debt has ranged from 10,000.00 to 10,000.00. According to the industry distribution chart, Cynata Therapeutics ranks #5 out of 1393 companies in the Biotechnology industry, placing it in the top 0.40000000000001%.
Is Cynata Therapeutics' Cash-to-Debt too high?
Cynata Therapeutics' current Cash-to-Debt of No Debt (1) is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 10,000.00 to a high of 10,000.00. Based on the distribution chart, Cynata Therapeutics ranks #5 out of 1393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Cynata Therapeutics' Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cynata Therapeutics ranks #5 out of 1393 companies for Cash-to-Debt. This places Cynata Therapeutics in the top 0% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 6.72. Historically, Cynata Therapeutics' own Cash-to-Debt has ranged from 10,000.00 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.72, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cynata Therapeutics's current Cash-to-Debt is No Debt (1), which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cynata Therapeutics stock overvalued right now?
Cynata Therapeutics (CYYNF) has a current Cash-to-Debt of No Debt (1). The current Cash-to-Debt is No Debt (1), which is 100% below median its 10-year median of 10,000.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Cynata Therapeutics (CYYNF), the current Cash-to-Debt is No Debt (1) as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus manufacturing platform. There are currently three active clinical trials taking place using Cymerus technology, which are attempting to treat osteoarthritis and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CYYNF has been successfully added to your 
